EUVIMEDEUVIMED entdecken
Crossref

Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

Tatsuro Tamura, Takahiro Toyokawa, Shigeru Lee, Takemi Ishidate, Katsunobu Sakurai, Naoshi Kubo, Sota Deguchi, Yuki Seki, Kenji Kuroda, Hiroaki Kasashima, Yuichiro Miki, Mami Yoshii und 3 weitere

Anticancer Research · 2026-08 · 46 (8) · 4461-4469

DOI: 10.21873/anticanres.18302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Tatsuro Tamura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; d21528w@omu.ac.jp. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Fluorouracil, Esophageal Squamous Cell Carcinoma, Antineoplastic Combined Chemotherapy Protocols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyFluorouracilEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansFemaleCisplatinAgedDocetaxelMiddle AgedMaleRetrospective StudiesFeasibility StudiesDrug Administration Schedule

Stichwörter der Autor:innen

Esophageal squamous cell carcinomaand 5-fluorouracilbiweekly divided-dose DCFcisplatindocetaxeldose intensityneoadjuvant chemotherapy

Substanzen

FluorouracilCisplatinDocetaxel

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; d21528w@omu.ac.jp.
  • Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Gastroenterological Surgery, Nakagami Hospital, Okinawa, Japan.
  • Department of Gastroenterological Surgery, Osaka City General Hospital, Osaka, Japan.
  • Department of Surgery, Baba Memorial Hospital, Sakai, Japan.

Zitieren

APA

Tamura, T., Toyokawa, T., Lee, S., Ishidate, T., Sakurai, K., Kubo, N., Deguchi, S., Seki, Y., Kuroda, K., Kasashima, H., Miki, Y., Yoshii, M., Shibutani, M., Ohira, M., & Maeda, K. (2026). Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer Research, 46(8), 4461-4469. https://doi.org/10.21873/anticanres.18302

Vancouver

Tamura T, Toyokawa T, Lee S, Ishidate T, Sakurai K, Kubo N, et al. Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Anticancer Research. 2026;46(8):4461-4469. doi:10.21873/anticanres.18302

BibTeX
@article{Tamura2026,
  author = {Tamura, Tatsuro and Toyokawa, Takahiro and Lee, Shigeru and Ishidate, Takemi and Sakurai, Katsunobu and Kubo, Naoshi and Deguchi, Sota and Seki, Yuki and Kuroda, Kenji and Kasashima, Hiroaki and Miki, Yuichiro and Yoshii, Mami and Shibutani, Masatsune and Ohira, Masaichi and Maeda, Kiyoshi},
  title = {Safety and Feasibility of Biweekly Divided-dose of DCF as Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {8},
  pages = {4461--4469},
  doi = {10.21873/anticanres.18302}
}
Kostenlos starten →